Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 60

  • 755 clinical trials
  • 276 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Obesity122Type 2 diabetes mellitus85Overweight58Type 1 diabetes mellitus41Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Iron deficiency8+215

Clinical trials in Metabolism and nutrition disorders

755 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

755 clinical trials

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on Fecal Microbiota Capsules vs. Placebo for Treating Non-Alcoholic Steatohepatitis in Patients

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Mikrobiomik Healthcare Company S.L.

PIK3CA related overgrowth spectrum+1

Not recruiting

Long-term Safety Study of Miransertib for Patients with PIK3CA-related Overgrowth Spectrum or Proteus Syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Miransertib
  • Sponsor:Merck Sharp & Dohme LLC

Type 2 diabetes mellitus

Not recruiting

Study on Heart Health in Type 2 Diabetes Patients Using Semaglutide and Dapagliflozin Combination

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Atenolol
  • Sponsor:Odense University Hospital

Insulin resistance

Not recruiting

Study on Pravastatin's Effect on Insulin Resistance in Kidney Transplant and Chronic Kidney Disease Patients

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Glucose Bp
  • Sponsor:Region Midtjylland

Glycogen storage disease type V+2

Not recruiting

Study on the Effects of EDG-5506 in Adults with Becker Muscular Dystrophy, McArdle Disease, or Limb-Girdle Muscular Dystrophy

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:EDG-5506
  • Sponsor:Edgewise Therapeutics Inc.

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on the Safety and Effects of AZD4831 for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) with Fibrosis

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AZD4831
  • Sponsor:AstraZeneca AB

Ornithine transcarbamoylase deficiency

Not recruiting

Long-Term Study on the Safety of Avalotcagene Ontaparvovec for Adults with Late-Onset Ornithine Transcarbamylase Deficiency

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avalotcagene Ontaparvovec
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Type 2 diabetes mellitus

Not recruiting

Study on Ertugliflozin for Children and Teens with Type 2 Diabetes

Investigational
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Ertugliflozin
  • Sponsor:Merck Sharp & Dohme LLC

Prader-Willi syndrome

Not recruiting

Study on the Safety and Effects of PBF-999 for Patients with Prader-Willi Syndrome

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:PBF-999
  • Sponsor:Palo Biofarma S.L.

Type 1 diabetes mellitus

Not recruiting

Study on Colchicine for Reducing Inflammation in Patients with Type 1 Diabetes

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Gentofte Hospital

Lipoprotein metabolism disorder

Not recruiting

Study of LY3819469 for Adults with High Lipoprotein(a) Levels

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:LY3819469 sodium
  • Sponsor:Eli Lilly & Co.

Obesity+1

Not recruiting

Study Comparing Tirzepatide and Semaglutide for Weight Loss in Adults with Obesity or Overweight and Related Health Issues

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY3298176
  • Sponsor:Eli Lilly & Co.

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide77 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsTirzepatide17 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsMetformin12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.